Sign In / Join

close

Clinical Trials

Our Clinical Trials articles highlight top clinical trials, their results, and how patients can participate in them.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

How Effective is R-CHOP vs BR Treatment for Follicular Lymphoma?

December 03, 2024

Read the latest findings from Dr. Baron and her team at Huntsman Cancer Institute on the efficacy of BR versus R-CHOP in treating follicular lymphoma.

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

November 19, 2024

Learn how golcadomide in combination with R-CHOP helped DLBCL patients in a phase 1 clinical trial.

New Clinical Trial with Armored CAR T-cells

October 01, 2024

Understanding CAR T-Cell Therapy and the Armored CAR T-Cell Trial

What are Clinical Trials, and How May They Help Me?

September 30, 2024

Learn about clinical trials to open the door to accessing innovative cancer treatments.

Bendamustine to Treat Follicular Lymphoma

July 23, 2024

Learn about bendamustine, a treatment option for follicular lymphoma. Discover how it works, potential side effects, and important safety considerations.

Glofitamab (Columvi) to Treat Relapsed or Refractory DLBCL

May 20, 2024

Columvi (Glofitamab) To Treat Relapsed Or Refractory DLBCL, new treatment option for DLBCL, Clinical Trial for DLBCL

Brentuximab Vedotin Combo Shows Improvement in DLBCL Survival

April 25, 2024

New study shows Brentuximab Vedotin combined therapy effective for relapsed DLBCL (lymphoma). Learn about ADCETRIS and its side effects.

MSKCC’s Clinical Trial: Reversing CAR T-cell Exhaustion with Antioxidants

October 16, 2023

Dr. Gunjan L. Shah and her team at MSK in NY are conducting a clinical trial to reverse T-cell exhaustion by pairing antioxidants alongside CAR T-cell therapy.

Promising Results Treating Relapsed and Refractory Follicular Lymphoma with Zanubrutinib & Obinutuzumab

October 10, 2023

A non-chemo treatment combination of zanubrutinib and obinutuzumab evaluated in the ROSEWOOD study showed promising treatment results.

The FDA Approves Columvi For Relapsed/Refractory DLBCL

October 08, 2023

The Food and Drug Administration (FDA) approved Columvi (glofitamab-gxbm) to treat adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Charity Navigator

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Tax ID 45-5354811

Clinical Trials

Recent Articles

How Effective is R-CHOP vs BR Treatment for Follicular Lymphoma?

DLBCL Clinical Trials: Promising Phase 1 Results of Golcadomide + R-CHOP

New Clinical Trial with Armored CAR T-cells

What are Clinical Trials, and How May They Help Me?

Bendamustine to Treat Follicular Lymphoma

Glofitamab (Columvi) to Treat Relapsed or Refractory DLBCL

Brentuximab Vedotin Combo Shows Improvement in DLBCL Survival

MSKCC’s Clinical Trial: Reversing CAR T-cell Exhaustion with Antioxidants

Promising Results Treating Relapsed and Refractory Follicular Lymphoma with Zanubrutinib & Obinutuzumab

The FDA Approves Columvi For Relapsed/Refractory DLBCL

Get the latest thought leadership on your Non-Hodgkin Lymphoma delivered straight to your inbox

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info